What It Is
Ipamorelin is a synthetic pentapeptide (a chain of five amino acids) classified as a growth hormone secretagogue. The National Cancer Institute describes it as a ghrelin mimetic that binds the growth hormone secretagogue receptor (GHSR) and stimulates growth hormone release from the pituitary gland.[1] Unlike synthetic human growth hormone, which replaces GH directly, ipamorelin prompts the body's own pituitary cells to release more of it.
Early pharmacology research described ipamorelin as more "selective" than older growth hormone releasing peptides such as GHRP-6, because it stimulated GH release without the same rise in cortisol and ACTH seen with those compounds at tested doses.[2] That selectivity refers to hormone specificity in early studies, not an established safety advantage in humans.
How It Works
Ipamorelin activates the growth hormone secretagogue receptor, mimicking the body's natural hormone ghrelin. Receptor activation triggers pituitary release of growth hormone, which then promotes IGF-1 production, mainly via the liver.[1] A human pharmacokinetic-pharmacodynamic study measured this GH response directly, modeling exposure and hormone output after controlled intravenous infusion in healthy male volunteers across a range of doses.[3]
Stimulating a hormone pulse in a controlled study is a measurable pharmacologic effect, but it is not proof of a durable clinical benefit. Improvements in body composition, sleep, or recovery require evidence tracking those actual outcomes over time — a much higher bar than a short-term GH spike.
What the Research Shows
Human research on ipamorelin is narrower than online marketing suggests. Beyond the healthy-volunteer GH-response study, the most substantial clinical trial tested intravenous ipamorelin for postoperative ileus after bowel resection: a randomized, placebo-controlled proof-of-concept study of 117 patients found a median time to first tolerated meal of 25.3 hours with ipamorelin versus 32.6 hours with placebo — a difference that was not statistically significant.[4]
Commonly repeated claims about fat loss, lean muscle, better sleep, tissue repair, and anti-aging are largely extrapolated from broader growth hormone and IGF-1 biology, not demonstrated in ipamorelin-specific human trials. For comparison, a related but distinct peptide, tesamorelin, carries an FDA-approved indication for reducing excess abdominal fat in people with HIV-associated lipodystrophy — a narrow, approved use with no bearing on ipamorelin's unapproved status.[7]
Safety & Side Effects
In the postoperative ileus trial, treatment-emergent adverse events occurred in 87.5% of ipamorelin patients versus 94.8% of placebo patients — a signal specific to that monitored surgical, intravenous setting, not a general safety verdict for outpatient use.[4] In a 2024 compounding review, FDA reviewers separately identified adverse events reported for ipamorelin-related substances, including hypokalemia, insomnia, hyperglycemia, nausea, vomiting, abdominal distention, and some deaths for which causality could not be determined.[5]
Broader concerns tied to GH-axis stimulation include:
- Glucose intolerance and diabetes risk
- Abnormal tissue growth and neoplasm risk
- Cardiovascular effects
- Immunogenicity, aggregation, and peptide-related impurities in compounded or research-grade material
- Lack of adequate safety data for proposed subcutaneous (self-injection) use, as opposed to the intravenous, hospital-monitored route used in published trials
Regulatory Status
Ipamorelin has no FDA-approved drug product and no approved labeled indication in the United States for growth hormone deficiency, fat loss, muscle growth, sleep, or anti-aging.[5] In a 2024 Pharmacy Compounding Advisory Committee review, the FDA placed ipamorelin acetate on its list of bulk substances presenting significant safety risks for compounding, citing immunogenicity, aggregation, peptide impurities, unnatural amino acids, and serious adverse events — including deaths of unclear causality — associated with intravenous use, alongside a lack of safety data for other injectable routes.[6]
For athletes, growth hormone secretagogues including ipamorelin are listed among prohibited substances on the World Anti-Doping Agency's Prohibited List.[17] Products marketed as research-grade ipamorelin sold outside these regulatory frameworks are not reviewed for sterility, purity, or accurate dosing.